NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active diseaseOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.